Sarrath Sutthipong, Dr1, Panot Yimcharoen, Dr1, Suthipong Treeratana, Dr2, Setthasiri Pantanakul1. 1Bhumibol Adulyadej Hospital, 2Private Practice
Background: Obesity has been a growing concern worldwide. There is a spectrum of measures to aid with weight loss, ranging from dietary modulation to surgical measures. Intra-gastric balloons (IGBs) are one of the modalities studied and currently in practice. We report 17 cases of IGB SPATZ3® adjustable balloon outcomes (body weight [BW], body mass index [BMI]) and appetite related sensation score (satiety scale) was assessed by a visual analogue scale [VAS].
Methods: Seventeen Asian obese patients (defined as BMI ≥ 25.0 kg/m2; according to Asian specific definitions for obesity) was studied prospectively after IGB placement. There were 15 females and 2 males, with a mean age of 33.4±12.3 years. The intra-gastric balloon devices was placed endoscopically in the stomach and filled with a volume of 350-500 mL.under intravenous sedation. Data was collected at 1- and 6-months period-during the follow-up visits were: BW, BMI and appetite related sensation score (hunger scale; range 0-10 [defined by starving and beyond as 0 to very uncomfortable full as 10, respectively]). All data were expressed as median (range).
Results: Baseline values were; BW 77.7 (61.7-106), BMI 30.4 (26.4-35) and hunger scale 8 (7-8). In all cases balloon insertion was mainly uneventful except one case having clinically nausea and vomiting at day-1 post-IGB placement (improvement with supportive treatment), 2 cases having vomiting problem, 1 case had severe vomiting within 4 days after placement then balloon removal was done, another case had intermittent vomiting during 1- month after placement and asked for cessation of this procedure however this patient was satisfy for the weight-loss result. One case required adjusting by refill the balloon from 450 mL to 650 mL due to lack of weight loss and the other case is during the follow-up period, no any complications were detected. After the follow-up period, all parameters exhibited a trend to reduction: BW 72.6 (56.5-100), BMI 28.4 (23.8-32.6) and hunger scale 5 (2-6) at 1 month and BW 68.7 (57.2-90.2), BMI 27.0 (21.8-33.3) and hunger scale 6 (6-8) at 6 months, respectively.
Conclusions: Based on our series, IGB placement in Asian patient showed the benefit result. We found the complication about vomiting problems but no major complication that required aggressive management was found in our series. However, there is a need to study our experience with a larger population of patients who have had this device inserted to report the benefit and safety of its use.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 79168
Program Number: P512
Presentation Session: Poster (Non CME)
Presentation Type: Poster